Antikörper-basierte Immuntherapien gegen Morbus Parkinson

Currently, there are no disease‑modifying therapies available for patients suffering from Parkinson’s disease (PD) and inevitably their motor and non‑motor symptoms are progressing over time. Aggregation of the misfolded protein alpha‑synuclein (aSyn) is considered a hallmark in the pathogenesis of PD. Aggregated aSyn can propagate from cell‑to‑cell in the peripheral and central nervous system. For almost twenty years research has been conducted into immunotherapies primarily targeting aggregated aSyn and its propagation. Several approaches using active or passive immunization are now being investigated in clinical trials. In this review, we are discussing the molecular background, the current state, and challenges in the development of antibody‑based immuno‑ therapies for PD.